New York, NY / June 18, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Mr. Elam shares why he believes the Company’s lead diabetes product candidate, AB101, is unique in comparison to basal insulin replacement therapies already available. He states, “Initial studies show that AB101 functions similarly to human insulin at the insulin receptor and IGF-1R.” Read the full blog post from Mr. Nevan Elam on TheChairmansBlog.com (http://www.thechairmansblog.com/antriabio/nevan-elam/smart-science-behind-ab101/).
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit: www.antriabio.com.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com